当前位置： SCI文献检索 > ADVANCED DRUG DELIVERY REVIEWS期刊下所有文献 > NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells.

NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells.

Abstract：

:Circulating tumor cells (CTCs) are cancer cells shredded from either a primary tumor or a metastatic site and circulate in the blood as the potential cellular origin of metastasis. By detecting and analyzing CTCs, we will be able to noninvasively monitor disease progression in individual cancer patients and obtain insightful information for assessing disease status, thus realizing the concept of "tumor liquid biopsy". However, it is technically challenging to identify CTCs in patient blood samples because of the extremely low abundance of CTCs among a large number of hematologic cells. In order to address this challenge, our research team at UCLA pioneered a unique concept of "NanoVelcro" cell-affinity substrates, in which CTC capture agent-coated nanostructured substrates were utilized to immobilize CTCs with remarkable efficiency. Four generations of NanoVelcro CTC assays have been developed over the past decade for a variety of clinical utilities. The 1st-gen NanoVelcro Chips, composed of a silicon nanowire substrate (SiNS) and an overlaid microfluidic chaotic mixer, were created for CTC enumeration. The 2nd-gen NanoVelcro Chips (i.e., NanoVelcro-LMD), based on polymer nanosubstrates, were developed for single-CTC isolation in conjunction with the use of the laser microdissection (LMD) technique. By grafting thermoresponsive polymer brushes onto SiNS, the 3rd-gen Thermoresponsive NanoVelcro Chips have demonstrated the capture and release of CTCs at 37 and 4 °C respectively, thereby allowing for rapid CTC purification while maintaining cell viability and molecular integrity. Fabricated with boronic acid-grafted conducting polymer-based nanomaterial on chip surface, the 4th-gen NanoVelcro Chips (Sweet chip) were able to purify CTCs with well-preserved RNA transcripts, which could be used for downstream analysis of several cancer specific RNA biomarkers. In this review article, we will summarize the development of the four generations of NanoVelcro CTC assays, and the clinical applications of each generation of devices.

journal_name

Adv Drug Deliv Rev

journal_title

Advanced drug delivery reviews

authors

Jan YJ,Chen JF,Zhu Y,Lu YT,Chen SH,Chung H,Smalley M,Huang YW,Dong J,Chen LC,Yu HH,Tomlinson JS,Hou S,Agopian VG,Posadas EM,Tseng HR

doi

10.1016/j.addr.2018.03.006

subject

Has Abstract

pub_date

2018-02-01 00:00:00

pages

78-93

eissn

0169-409X

issn

1872-8294

pii

S0169-409X(18)30045-0

journal_volume

125

pub_type

杂志文章,评审

在线工具

NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells.